Services

Inquiry and ordering

Name*
Phone*
Email*
Product*
Content*

Affibody Screening Services

TekBiotech, leveraging its extensive expertise in bovine antibody production technology, offers bovine Ultralong CDR H3 affibody screening services to customers worldwide. Bovine Ultralong CDR H3 affibodies feature a unique “stalk-knob” structure, in which the “knob” serves as an independent, stable target antigen-binding domain and is the key region responsible for their biological activity, while the long “stalk” structure enables the “knob” to reach “hidden” epitopes—such as those inaccessible to macromolecular targeted drugs (e.g., antibodies)—much like a tentacle. These characteristics make it possible to use bovine Ultralong CDR H3 affibodies to develop neutralizing small-molecule drugs and therapeutic small-molecule drugs for diseases related to viruses, inflammation, and tumors, as well as for many “hard-to-drug” targets (i.e., “hidden” functional epitope targets). The discovery of bovine Ultralong CDR H3 affibodies is of great significance for the future development of therapeutic drugs for many intractable diseases.

Bovine Ultralong CDR H3 affibody have a small molecular weight (only 4–6 kDa), exhibit high stability and strong tissue penetration, and are capable of binding to antigens independently of the antibody structure. Therefore, bovine Ultralong CDR H3 affibody are also referred to as “picobodies” and can be used to construct minimalized bispecific or multispecific antibodies.

TekBiotech is committed to providing clients with high-quality affibody screening services, offering strong support for their subsequent affibody-based drug development. TekBiotech also offers downstream product development services and drugability evaluations (including affibody synthesis, affinity detection, functional detection of signaling pathway inhibition, and animal model detection). After 10 years of development, TekBiotech has established a comprehensive affibody screening system, enabling it to provide clients with affibody screening services for a wide range of disease-related signaling pathway targets, including transmembrane proteins and ion channels.

█ Affibody Screening Services

The affibody screening service is based on bovine antibody production technology. Bovines are immunized with engineered antigens (primarily designed to expose the natural functional domains of the target) to generate relevant antibodies. Specific B cells are isolated via FACS, and an Ultralong CDR H3 affibody library is generated through multiple rounds of PCR amplification. The relevant affibody sequences are then obtained through NGS sequencing and analysis. The affinity of the affibody screened by TekBiotech can reach the μM–nM range. Furthermore, the company designs appropriate screening antigens based on the structural characteristics of the target and combines them with customized screening strategies to perform the screening. The procedure for the bovine Ultralong CDR H3 affibody screening service is shown in Figure 1:

图1 亲合体筛选流程.png

Figure 1: Affibody Screening Service Procedure

TekBiotech’s scientists will recommend the most suitable affibody screening solution based on the client’s target and project requirements, in order to obtain high-affinity affibody that are suitable for downstream experimental applications. Clients need only provide their target and project requirements, and TekBiotech’s scientists will design and provide a customized solution strategy tailored to their needs, thereby saving clients time and resources.

█ Affibody Screening Service Details and Timeline

Steps	Service Details	Weeks
Step 1: Animal Immunization	(1) Administer the antigen to healthy adult bovine 4–5 times; (2) Detection the titer using an ELISA; (3) If the titer meets the requirements, isolate PBMCs or lymphocytes;	10 weeks
Step 2: FACS Sorting and Sequencing	(1) FACS dual-fluorescence sorting of PBMCs or lymphocytes; (2) Total RNA extraction and cDNA synthesis; (3) 3 rounds of PCR amplification for identification and product recovery, followed by NGS sequencing and sequence analysis;	6-8 weeks
Step 3: Detection of the Ultralong CDR H3 Affibody	(1) Synthesize the Ultralong CDR H3 affibody; (2) Detect binding to antigen-overexpressing cell lines via FACS; (3) Detect affinity via BLI/SPR;	3-4 weeks

█ Advantages of the Affibody Screening Service


One-Stop Service	Mature Technology Platform	Screening Targets Associated with Various Diseases	Customized Solutions
One-stop service from affibody discovery to drug efficacy evaluation	The affinities of the affibody identified through screening are generally in the μM–nM range.	Multitransmembrane proteins, ion channels, “hidden” epitope targets, etc.	Meeting the research project needs of all types of customers